Application of an improved ELISA assay to the analysis of urinary estrogen metabolites

Steroids

Volumn 63, Issue 7-8, 1998, Pages 406-413

  Bradlow, H Leon ^a   Sepkovic, Daniel W ^a   Klug, Thomas ^b   Osborne, Michael P ^a  

^a Strang Cancer Research Laboratory   (United States)

^b Immuna Care Corporation   (United States)

Author keywords

16 hydroxyestrone; 2 hydroxyestrone; Breast cancer risk; ELISA; Estrogen metabolites; Postmenopausal; Urinary assay

Indexed keywords

ESTRONE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESTROGEN METABOLISM; ESTROGEN URINE LEVEL; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; REPRODUCIBILITY; RISK ASSESSMENT; SEX HORMONE DETERMINATION; URINALYSIS; UTERINE CERVIX CANCER;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGENS; FEMALE; HUMANS; HYDROXYESTRONES; PREMENOPAUSE; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS;

EID: 0031866388     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(98)00041-5     Document Type: Article

References (26)

1. Kabat G.C., Chang C.J., Sparano J.A., Sepkovic D.W., Hu X.P., Khalil A., Rosenblatt R., Bradlow H.L. Urinary estrogen metabolites and breast cancer A case-control study . Cancer Epidemiol Biomarkers Prev. 6:1997;500-504.
2. Crane MM, Sepkovic DW, Robertson NK, Lopez A, Blackhurst DW, Sticca RP, Coker AL, Bradlow HL (1996). Association of estrogen urinary metabolites and breast cancer: Pilot study. submitted.
3. Zheng W., Dunning L., Gong Y., Anderson K., Xiao-ou S., Sellers T., Potter J., Jin F., Hotzman J. Ratios of urinary 2-hydroxyestrone to 16α-hydroxyestrone are lower in breast cancer patients than controls. Cancer Epidemiol Biomarkers Prev. 7:1998;85-86.
4. Sepkovic DW, Bradlow HL, Ho G, Hankinson SE, Gong L, Osborne MP, Fishman J (1995). Estrogen metabolite ratios and risk assessment of hormone-related cancers: Assay validation and prediction of cervical cancer risk. In: Bradlow HL, Osborne MP, Veronesi U. (eds). Cancer Prevention. Ann NY Acad Sci 758:312-316.
5. Naganuma H., Hershcopf R.J., Michnovicz J.J., Miyairi S., Bradlow H.L., Fishman J. Radioimmunoassay of 16α-hydroxyestrone in human urine. Steroids. 53:1989;37-48.
6. Klug T.L., Bradlow H.L., Sepkovic D.W. Monoclonal antibody-based enzyme immunoassay for simultaneous quantitation of 2- and 16α-hydroxyestrone in urine. Steroids. 58:1994;648-654.
7. Ziegler R.G., Rossi S.C., Fears T.R., Bradlow H.L., Adlercreutz H., Sepkovic D.W., Kiuru P., Wahala K., Vaught J.B., Donaldson J.L., Falk R.T., Fillmore C.-M., Siiteri P.K., Hoover R.N., Gail M.H. Quantifying estrogen metabolism An evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16α-hydroxyestrone in urine . Environ Health Perspect. 105:(Suppl. 3):1997;607-614.
8. Ursin G., London S., Stanczyk F.Z., Gentzschein E., Paganini-Hill A., Ross R.K., Pike M.C. A pilot study of urinary estrogen metabolites (16α-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. Environ Health Perspect. 105:(Suppl 3):1997;601-605.
9. Ruiz-Larrea M.B., Leal A.M., Liza M., Lacort M., De Groot H. Antioxidant effects of estradiol and 2-hydroxyestradiol on iron induced lipid peroxidation of rat liver microsomes. Steroids. 1996;in press.
10. Schneider J., Huh M.M., Bradlow H.L., Fishman J. Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem. 259:1984;4840-4845.
11. Suto A., Bradlow H.L., Wong G.Y., Osborne M.P., Telang N.T. Experimental down-regulation of intermediate biomarkers of carcinogenesis in mouse mammary epithelial cells. Breast Cancer Res Treat. 27:1993;193-202.
12. Telang N.T., Suto A., Wong G.Y., Osborne M.P., Bradlow H.L. Estrogen metabolite 16α-hydroxyestrone induces genotoxic damage and aberrant cell proliferation in mouse mammary epithelial cells in culture. J Natl Cancer Instit. 84:1992;634-638.
13. Lemon H.M., Heidel J.W., Rodriguez-Sierra J.F. A method for estimating catechol estrogen metabolism from excretion of non-catechol estrogens. Cancer (Phila.). 68:1991;444-450.
14. Schutze N., Vollmer G., Tiemann I., Geiger M., Knuppen R. Catechol estrogens are MCF-7 estrogen receptor agonists. J Steroid Biochem Mol Biol. 46:1993;781-789.
15. Bradlow H.L., Telang N.T., Sepkovic D.W., Osborne M.P. 2-hydroxyestrone The "good" estrogen international symposium on DHEA transformation into androgens and estrogens in target tissues . J Endocrinol. 150:1997;S259-S265.
16. Levey S., Jenning E.R. The use of control charts in clinical chemistry. Am J Clin Path. 20:1950;1059-1066.
17. Pasagian-McCauley A., Meilahn E.N., Bradlow H.L., Sepkovic D.W., Buhari A.M., Simkin-Silverman L., Wing R.R., Kuller L.H. Urinary markers of estrogen metabolism 2- and 16α-hydroxylation in premenopausal women. Steroids. 61:1996;461-467.
18. Wong G.Y.C., Bradlow H.L., Sepkovic D.W., Mehl S., Mailman J., Osborne M.P. A dose-ranging study of indole-3-carbinol for breast cancer. J. Cell Biochem. 1998;in press.
19. Westerlind K.C., Gibson K.G., Wolfe P. Diurnal and menstrual cycles of 2- and 16α-hydroxyestrones in reproductive age women. Proc Endocr Soc. 1997;1494.
20. Bulbrook R.D., Hayward J.L. Abnormal urinary steroid excretion and subsequent breast cancer. A prospective study in the Island of Guernsey. Lancet. 489:1967;519-522.
21. Meilahn EN, De Stavola B, Allen DS, Fentima I, Bradlow HL, Sepkovic DW, Kuller LH (1998). Do urinary estrogen metabolites predict breast cancer? Follow up of the Guernsey III cohort. Br J Cancer, in press.
22. Chen C., Malone K.E., Prunty J., Daling J.R. Measurement of urinary estrogen metabolites using a monoclonal enzyme-linked immunoassay kit Assay performance and feasibility for epidemiological studies . Cancer Epidemiol Biomark Prev. 5:1996;727-732.
23. Bradlow H.L., Sepkovic D.W., Telang N.T. Correspondence re Chen C, Malone KE, Prunty J, Daling JR (1996). Measurement of urinary estrogen metabolites using a monoclonal enzyme-linked immunoassay kit: Assay performance and feasibility for epidemiological studies . Cancer Epidemiol Biomark Prev. 6:1977;145-147.
24. Taioli E., Trachtman J., Chem X., Sepkovic D.W., Bradlow H.L., Toniolo P. Correlation of estradiol 2-hydroxylation and breast cancer risk in patients carrying the MSP-1 polymorphism of CyP4501A1. AACR Proceedings #1697. 1996;142.
25. Taioli E, Bradlow HL, Sepkovic DW, Garbers S, Trachman J, Gartes SJ (1998). Cyp1A1 genotype, estradiol metabolism and breast cancer in African-Americans. Cancer Detect Prevent, in press.
26. Rosen CA, Thompson JW, Woodson GE, Hengesteg AP, Bradlow HL (1998). Preliminary results of the use of indole-3-carbinol for recurrent papillomatosis. Otolaryngol Head Neck Surg 118:, in press.